Safety & Effectiveness of Duodenal Mucosal Resurfacing (DMR) Using the Revita™ System in Treatment of Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 28, 2018

Primary Completion Date

August 10, 2020

Study Completion Date

August 10, 2020

Conditions
Type 2 Diabetes
Interventions
DEVICE

Duodenal Mucosal Resurfacing (DMR)

The Fractyl DMR procedure utilizes the Revita™ Catheter to perform hydrothermal ablation of the duodenum. The catheter is delivered trans-orally over a guide-wire to first inject saline to lift the sub-mucosal space, followed by an ablation of the duodenal mucosa. Subjects who receive the DRM treatment are followed for 48 weeks while Sham subjects who cross over and undergo the DMR procedure at 24 weeks are followed for further 24 weeks post treatment. Sham subjects who choose not to cross over are discontinued from the study.

DEVICE

Duodenal Mucosal Resurfacing Sham (Sham)

The Sham procedure consists of placing the Revita™ Catheter as described above into the duodenum for a minimum of 30 minutes and then removing it from the patient.

Trial Locations (6)

19104

University of Pennsylvania - Penn Metabolic Medicine, Philadelphia

32804

Florida Hospital / TRANSLATIONAL RESEARCH INSTITUTE FOR METABOLISM AND DIABETES (TRI), Orlando

77030

UTHealth, Houston

78229

Texas Diabetes Institute, San Antonio

02115

Brigham and Women's Hospital, Boston

03756

Dartmouth Hitchcock Medical Center, Lebanon

Sponsors
All Listed Sponsors
lead

Fractyl Health Inc.

INDUSTRY